Sarepta Therapeutics Inc (SRPT) : Group One Trading scooped up 508,268 additional shares in Sarepta Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 571,145 shares of Sarepta Therapeutics Inc which is valued at $14,427,123.Sarepta Therapeutics Inc makes up approximately 1.25% of Group One Trading’s portfolio.
Other Hedge Funds, Including , Citadel Advisors reduced its stake in SRPT by selling 1,357,309 shares or 89.18% in the most recent quarter. The Hedge Fund company now holds 164,743 shares of SRPT which is valued at $4,161,408. Sarepta Therapeutics Inc makes up approx 0.01% of Citadel Advisors’s portfolio.Credit Suisse Ag reduced its stake in SRPT by selling 389,984 shares or 86.13% in the most recent quarter. The Hedge Fund company now holds 62,826 shares of SRPT which is valued at $1,586,985. Canada Pension Plan Investment Board sold out all of its stake in SRPT during the most recent quarter. The investment firm sold 23,400 shares of SRPT which is valued $591,084. Oppenheimer Co Inc added SRPT to its portfolio by purchasing 20,213 company shares during the most recent quarter which is valued at $501,282. Sarepta Therapeutics Inc makes up approx 0.01% of Oppenheimer Co Inc’s portfolio.
Sarepta Therapeutics Inc opened for trading at $26.73 and hit $27.73 on the upside on Monday, eventually ending the session at $27.4, with a gain of 2.32% or 0.62 points. The heightened volatility saw the trading volume jump to 14,03,421 shares. Company has a market cap of $1,312 M.
On the company’s financial health, Sarepta Therapeutics Inc reported $-1.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $-1.21.Analysts expectations of $ .10.During the same quarter in the previous year, the company posted $-0.87 EPS.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Company shares were Reiterated by Needham on Jul 22, 2016 to “Buy”, Firm has raised the Price Target to $ 26 from a previous price target of $20 .Sarepta Therapeutics Inc was Upgraded by Piper Jaffray to ” Neutral” on Jun 9, 2016. Wedbush Upgraded Sarepta Therapeutics Inc on Jun 7, 2016 to ” Outperform”, Price Target of the shares are set at $36.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.